Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline‐Induced Cardiotoxicity Using an Integrated PK/PD Model
Mohamed S. Dabour, Anne H. Blaes, Pamala A. Jacobson, Mark N. Kirstein, Beshay N. Zordoky, Shen Cheng · 2026
Read Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline‐Induced Cardiotoxicity Using an Integrated PK/PD Model by Mohamed S. Dabour, Anne H. Blaes, Pamala A. Jacobson, Mark N. Kirstein, Beshay N. Zordoky, Shen Cheng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13165276.txt.
Description
Mohamed Dabour and co-authors test in 2026 whether a blood signal can give early warning of heart damage from a common cancer drug. Doxorubicin cures many breast cancers but can hurt the heart, and the usual warning mark rises late. The team built a math model of how the drug and a stress signal, GDF15, move together in seventeen patients.
Blood samples across two drug cycles fed the model. The stress signal rose fast, peaking near eight hours after dosing, while the standard mark peaked near thirty-four hours. Higher drug totals meant higher signal levels. The authors say the early signal could help sort patients by heart risk sooner.
Catalog record
| CREATOR | Mohamed S. Dabour, Anne H. Blaes, Pamala A. Jacobson, Mark N. Kirstein, Beshay N. Zordoky, Shen Cheng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |